课题基金 / 基金详情

CLONING OF THE PSEUDOHYPOPARATHYROIDISM TYPE 1B GENE

CLONING OF THE PSEUDOHYPOPARATHYROIDISM TYPE 1B GENE
1B 型假性甲状旁腺功能减退症基因的克隆
批准号:
6524419
负责人:
MICHAEL ALAN LEVINE
金额:
$26.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-01 至 2004-08-31

项目摘要

项目成果

MICHAEL ALAN LEVINE的其他基金

相似基金

相关文献

中文摘要
翻译
假性甲状旁腺功能减退症(PHP)1型是一种常染色体显性遗传性疾病,其特征是靶组织对甲状旁腺激素(PTH)产生抵抗而导致的生化甲状旁腺功能减退。已经描述了两种完全不同的PHP类型1。在PHP1a型中,GNAS1基因的突变导致G蛋白的α亚单位(Gsα)的表达或活性降低,该蛋白将PTH和许多其他激素的七螺旋受体连接到腺苷环化酶的激活。因此,Gsα的广泛缺乏不仅与对甲状旁腺素的抗药性有关,也与对其他通过刺激腺苷环化酶起作用的激素有关。相比之下,在PHP1b型中,Gsα是正常的,激素抵抗仅限于PTH靶组织。这些观察表明,PHP1b型的缺陷是1型PTH受体,但对该基因的分子分析尚未发现突变。本项目的目标是鉴定和鉴定PHP1b型的基因。我们使用连锁分析将PHP1b(指定为PHP1b)的基因座分配给10q26。该区域包含编码5G蛋白偶联受体激酶(GRK 5)的候选基因,GRK 5是一种可以使1型PTH受体磷酸化和脱敏的蛋白激酶。为了确定PHP1b基因,将使用定位克隆策略,包括以下方法:(1)首先通过对我们已确定的另外三个PHP1b类型家系的单倍型分析来进一步精炼PHP1b基因座,然后利用定位于该区域的额外的多态标记对所有家系进行进一步分析。(2)筛选可公开获得的YAC克隆,组装跨越该基因座的线性重叠群,提高物理图谱的分辨率。(3)通过查阅公开的EST图谱、GeneTrapper方法筛选文库和外显子捕捉法鉴定该区域的编码序列。(4)通过评估与其他已知基因的同源性、组织特异性表达模式和跨物种保护来确定转录本的特征。(5)对家族性和散发性病例的基因组DNA进行突变分析。一旦确定了PHP1b基因,长期目标将是确定基因产物的功能,检查基因与表型的相关性,并了解其在调节PTH受体在健康和疾病中的表达或作用方面的作用。
英文摘要
Pseudohypoparathyroidism (PHP) type 1 is an autosomal dominant disorder characterized by biochemical hypoparathyroidism due to resistance of target tissues to parathyroid hormone (PTH). Two fundamentally different forms of PHP type 1 have been described. In PHP type 1a, mutations in the GNAS1 gene lead to reduced expression or activity of the alpha subunit of the G protein (Gs alpha) that couples heptahelical receptors for PTH and many other hormones to activation of adenylyl cyclase. Accordingly, widespread deficiency of Gs alpha is associated with resistance not only to PTH but also to other hormones that act by stimulating adenylyl cyclase. By contrast, Gs alpha is normal in PHP type 1b, and hormone resistance is limited to PTH target tissues. These observations had suggested that the defect in PHP type 1b was the type 1 PTH receptor, but molecular analysis of this gene has not revealed mutations. The goal of this project is to identify and characterize the gene for PHP type 1b. We have used linkage analysis to assign the locus for PHP type 1b (designated PHP1b) to 10q26. This region contains a candidate gene that encodes the type 5 G protein-coupled receptor kinase (GRK 5), a protein kinase that can phosphorylate and desensitize the type 1 PTH receptor. To determine the PHP1b gene, a positional cloning strategy will be used involving the following approaches: (1) Further refine the PHP1b locus first by haplotype analysis of three additional PHP type 1b families we have ascertained, and subsequently by further analysis of all families using additional polymorphic markers mapped to this region. (2) Screen publicly available YAC clones and assemble a linear contig spanning the locus, and increase the resolution of the physical map. (3) Identify coding sequences in this region by review of publicly available EST maps, screening cDNA libraries by GeneTrapper methodology, and by exon-trapping. (4) Characterize transcripts through evaluation of homology to other known genes, patterns of tissue-specific expression, and cross-species conservation. (5) Perform mutational analysis of genomic DNA samples from familial and sporadic cases. Once the PHP1b gene is identified, the long-range goal will be to characterize the function of the gene product, to examine genotype-phenotype correlations, and to understand its role in regulating expression or action of the PTH receptor in health and disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
  • 批准号:
    10581278
  • 项目类别:
  • 资助金额:
    $63.18万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL ALAN LEVINE
  • 依托单位:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
  • 批准号:
    9388011
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL ALAN LEVINE
  • 依托单位:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
  • 批准号:
    9980393
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL ALAN LEVINE
  • 依托单位:
Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1
  • 批准号:
    10170333
  • 项目类别:
  • 资助金额:
    $45.2万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL ALAN LEVINE
  • 依托单位:
海外基金